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Abstract
MiR-34a acts as a candidate tumour suppressor gene, and its expression is reduced in several cancer types. We aimed to
study miR-34a expression in breast cancer and its correlation with tumour characteristics and clinical outcome, and
regulatory links with other genes. We analysed miR-34a expression in 1,172 breast tumours on TMAs. 25% of the tumours
showed high, 43% medium and 32% low expression of miR-34a. High miR-34a expression associated with poor prognostic
factors for breast cancer: positive nodal status (p=0.006), high tumour grade (p,0.0001), ER-negativity (p=0.0002), HER2-
positivity (p=0.0002), high proliferation rate (p,0.0001), p53-positivity (p,0.0001), high cyclin E (p,0.0001) and cH2AX
(p,0.0001). However, multivariate analysis adjusting for conventional prognostic factors indicated that high miR-34a
expression in fact associated with a lower risk of recurrence or death from breast cancer (HR=0.63, 95% CI=0.41–0.96,
p=0.031). Gene expression analysis by differential miR-34a expression revealed an expression signature with an effect on
both the 5-year and 10-year survival of the patients (p,0.001). Functional genomic analysis highlighted a novel regulatory
role of the transcription factor MAZ, apart from the known control by p53, on the expression of miR-34a and a number of
miR-34a targets. Our findings suggest that while miR-34a expression activation is a marker of aggressive breast tumour
phenotype it exerts an independent effect for a lower risk of recurrence or death from breast cancer. We also present an
expression signature of 190 genes associated with miR-34a expression. Our analysis for regulatory loops suggest that MAZ
and p53 transcription factors co-operate in modulating miR-34a, as well as miR-34a targets involved in several cellular
pathways. Taken together, these results suggest that the network of genes co-regulated with and targeted by miR-34a form
a group of down-stream effectors that maybe of use in predicting clinical outcome, and that highlight novel regulatory
mechanisms in breast cancer.
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Introduction
MicroRNAs (miRs) are short 18–24 nucleotide RNAs that work
as post-transcriptional regulators by binding to sequences in the 39
untranslated region (39 UTR) of target mRNAs either through
fully complementary or imperfect base-pairing, usually resulting in
mRNA silencing [1,2]. MiRs are estimated to regulate up to 30% of
all the protein coding genes in the human genome [3]. To date,
more than 9000 miRs have been identified in different species
according to the miRBase release 13.0 (http://microrna.sanger.ac.
uk/sequences/). Aberrant metabolism and expression of miRs have
been linked to a variety of diseases, including cancer, and several
miRs are thought to behave as oncogenes or tumour-suppressors as
they have different expression levels in cancer as compared to
normal tissues [4]. Components of the miR machinery as well as
miRs themselves are involved in many cellular processes altered in
cancer, such as differentiation, proliferation and apoptosis and they
are demonstrated to affect cellular transformation, carcinogenesis
and metastasis [5].
During the recent years, the miR-34 family has become a
promising topic in cancer research [6]. This miR family consists of
three members, namely miR-34a, miR-34b and miR-34c, which
are encoded by two different genes: miR-34a is transcribed from its
own independent locus, whereas miR-34b and miR-34c share a
common primary transcript. MiR-34a resides on the chromosomal
locus 1p36.23, and the loss of this region is associated with a variety
of cancer types [7]. MiR-34a is highly expressed in normal tissues,
like testis, lung, adrenal gland and spleen, where its physiological
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control of the tumour suppressor gene product p53 and it acts as a
tumour suppressor inducing cell cycle arrest in G1-phase [9,10],
senescence and apoptosis [11–13] in osteosarcoma and breast,
colon, lung and pancreatic cancer cell lines as well as in mouse
tissues, such as colon, kidney, spleen and thymus. This in turn leads
to reduction in the protein levels of cyclin D1 (CCND1) and cyclin-
dependent kinase 6 (CDK6),which regulates the phosphorylationof
retinoblastoma protein (pRb), as seen in non-small-cell lung cancer
cells [14]. MiR-34a is predicted to target hundreds of mRNAs, but,
to date, only a few of them have been experimentally verified,
including the oncogenes MYC, CDK6, SIRT1 and MET [15,16].
The expression of miR-34a has been observed to be reduced in
many types of cancers. In epithelial ovarian cancer (EOC), the
overall expression of the miR-34 family members is frequently
decreased, and is associated with metastatic clinical stage and
increased expression of c-MET [17]. Downregulation of miR-34a,
at least partly due to mutations in p53, has been seen in the cell
lines of chronic lymphocytic leukemia, as well as in pancreatic,
hepatocellular and colon carcinomas [13,18,19]. In non-small-cell
lung cancer tissue, low levels of miR-34a combined with p53
mutations were observed to correlate with a high probability of
relapse [20]. In breast cancer, miR-34 levels have been found
low in cell lines derived from ER/PR/HER2-negative (‘triple-
negative’) tumours, which may reflect the higher incidence of p53
mutations in this subtype [21]. Furthermore, the silencing of miR-
34a may also be mediated by CpG methylation of the region 100
to 500 base-pairs upstream of the miR-34a transcription start
which contains a p53 binding site [22]. CpG methylation of the
miR-34a promoter was also detected in 25% of breast cancer cell
lines. Finally, in several cancer types including breast cancer,
genomic deletions or loss of heterozygosity of the region have been
described [23]. The deletion in chromosome 1p also explains the
low level of miR-34a seen in neuroblastomas [24].
In this study, we focused on the expression of miR-34a in an
extensive series of human breast carcinomas. We investigated
miR-34a expression in breast tumours and its relationship with
tumour phenotype and prognosis. Additionally, we investigated
the overall transcriptional profile in tumours stratified by intensity
of miR-34a expression using genome-wide DNA microarray
assays. Finally, we dissected regulatory motifs that might underlie
the differential expression of miR-34a and investigated the survival
of the patients relative to the genes differentially expressed due to
miR-34a levels.
Methods
Patients
A series of 884 unselected breast cancer patients was recruited at
the Department of Oncology, Helsinki University Central Hospital,
during the years 1997–1998 [25] and 2000 [26] (79% of all con-
secutive, newly diagnosed breast cancer cases during the collection
periods). An additional familial breast cancer patient series (n=546)
was recruited at the Departments of Oncology and Clinical Genetics
[27]. For the tissue microarrays (TMAs), altogether 1356 inva-
sive breast cancer tumours were available. Detailed description of
methods is included in Supporting Information (File S1).
Ethics Statement
This study was performed with informed consent from the
patients as well as permissions from the Ethics Committee E9 of
the Helsinki University Central Hospital (Dnro 207/E9/07) and
from the Ministry of Social Affairs and Health in Finland.
Evaluation of immunoreactivity scores
Tissue microarray construction was performed as previously
described [28]. The means for locked nucleic acid in situ
hybridisation (LNA-ISH) for miR-34a are described in File S1.
MiRs exist in the cytoplasm, as previously described, and in this
study, category 1 represents weak cytoplasmic staining, category 2
moderate staining, category 3 being the highest intensity of
staining (Figure 1). The positive control in our samples was a small
nuclear non-coding RNA U6. The LNA probe for miR-34a used
in this study has proved to be specific and functional in at least two
previous studies, where the LNA-ISH results were concordant
with rt-pcr and northern blot analysis [17,29]. As a negative
control we used pre-designed scrambled negative control probe
(Exiqon). This probe has the same length and LNA content as the
LNA detection probe and possess minimal self-annealing proper-
ties. The scrambled miR-negative control probe has been blasted
in NCBI Blast for pre-miR and mature miR targets in miRBase
and bears no homology to any known microRNA or mRNA-
sequence.
Relationships between miR-34a levels and clinical
features
SPSS v.18.0 for MAC was used (SPSS, Inc.,Chicago, IL). P-values
forcomparisonsofmiR-34aandtumourhistopathologicaldifferences
were calculated using the linear Spearman rank correlation. To
account for the multiple variables tested, p-values,0.01 were
considered significant and all p-values are two-sided. Kaplan-Meier
survival analysis was used to estimate the effect of miR-34a on 10-
yearbreastcancer-specificand 5-year metastasis-free orbreast cancer
death survival rates on different patient series. Univariate and
multivariate Cox’s regression analysis were used to calculate the
hazard ratios for the effects of miR-34a expression on survival. ER-
and PR-status were considered as categorical variables. In the
multivariate analysis, T, N, M, grade, ER, PR, HER2, p53 and Ki67
were included in addition to the miR-34a result.
Gene expression microarray analysis
Total RNA was extracted from 183 breast tumours (GEO ID
GSE24450) collected at the Helsinki University Central Hospital.
The samples were processed and hybridiced to Illumina Human
HT-12 v3 Expression BeadChips, according to the manufacturer
recommendations (http://www.illumina.com). Microarray raw
data were processed by the methods included in the BioConductor
facilities [30] for R v2.11 (http://cran.r-project.org). Briefly, after
quality control [31] and normalization [32], the intensities of the
probes mapping to the same Entrez Gene IDs [33] were averaged.
A subset of 72 samples was also included in the miR-34a in situ
hybridisation. In this set of tumours, moderated t-test was applied to
find genes differentially expressed between the 13 samples with low
miR-34a expression (in situ score 1) and the 59 samples with high
miR-34a expression (in situ score 2 or 3). Genes with nominal
p,0.01 were considered differentially expressed and further
analysed. Functional annotation was performed on the differentially
expressed genes using the DAVID annotation tools [34].
Survival analysis based on the gene expression data
The miR-34a gene signature was analysed for having an effect
on the clinical outcome in the larger set of 183 tumours described
above (NCBI GEO accession number GSE24450) as well as in the
publicly available breast cancer gene expression data set of 249
unselected primary tumours (NCBI GEO accession number
GSE4922) [35]. Detailed description of these methods is contained
in File S1.
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The list of differentially expressed genes was screened for
potential targets of miR-34a by the integrated analysis of 9 different
algorithms available at miRWalk (http://www.ma.uni-heidelberg.
de/apps/zmf/mirwalk/).
Promoter analysis
A total of 688 promoter sequences of the differentially expressed
genes, including alternative promoters for the same loci, were
retrieved from the Genomatix (Genomatix, Munich, Germany)
and analysed for matches to the position weight matrices (PWM)
for the transcription factor binding sites (TFBS) by the Genomatix
MatInspector software using the default parameters [36].
Results
The expression of miR-34a was investigated in an extensive series
of breast tumours – altogether, samples from 1172 tumours were
scored for miR-34a. The remaining 5.4% (n=67) of the samples
were not analysed due to either unpresentative or missing tissue.
25% of the tumours showed high, 43% medium and 32% low
expression of miR-34a. The benign breast epithelium shows strong
staining with the miR-34a probe (Figure 1).
Correlation of miR-34a expression with tumour characteristics
is shown in Table 1. High miR-34a expression was associated with
a non-favourable tumour phenotype of positive nodal status
(p=0.006), high tumour grade (p,0.0001), ER-negativity
(p=0.0002), high proliferation rate (p,0.0001) as well as high
expression of HER2 (p=0.0002), p53 (p,0.0001) and cyclin E
(p,0.0001). In addition, miR-34a expression was also associated
with high degree of endogenous DNA damage estimated by
elevated cH2AX (p,0.0001), and with tumours of ductal origin
(p,0.0001) and premenopausal status (p=0.0001). High miR-34a
positively correlated with high cyclin D1 among ER-positive
patients (p=0.0004, data not shown). However, the expression of
miR-34a was not associated either with 10-year breast cancer-
specific survival [cumulative survival (CS)=78.9% vs. 84.4% for
the cases with high vs. low expression of miR-34a, p=0.285] or 5-
year metastasis-free or breast cancer death-free survival of the
patients (CS=81.7%, vs. 84.4% p=0.667). In univariate analysis
performed with Cox’s regression model, miR-34a showed no
significant effect either on 10-year breast cancer-specific survival
or 5-year metastasis-free or breast cancer death-free survival of the
patients (HR=1.16, 95% CI=0.96–1.40, p=0.12; HR=1.09,
95% CI=0.91–1.31, p=0.372). Since miR-34a expression was
strongly associated to several adverse prognostic factors for breast
cancer recurrence or death, we also performed a multivariate
Cox’s regression analysis with these factors included in order to
estimate the independent effect of the miR-34a on breast cancer
survival. In contrast to the univariate analysis, the multivariate
analysis showed that miR-34a expression had an independent
effect on a lower risk of recurrence or death from breast cancer
for the patients whose tumours had highest miR-34a expression
versus those with lowest miR-34a expression (HR=0.63, 95%
CI=0.41–0.96, p=0.031 for the 5-year metastasis-free or breast
cancer death-free survival) (Table 2). The effect on the 10-year
breast cancer-specific survival was not significant although a
similar tendency was seen (HR=0.80, 95% CI=0.50–1.25,
p=0.323).
Gene expression analysis by DNA microarrays was performed on a
subset of 72 samples of the 183 set, for which the miR-34a LNA-ISH
score was available. We compared the samples with low miR-34a
expression (LNA-ISH score 1) to the samples with high miR-34a
expression (LNA-ISH score 2 or 3), in order to distinguish between
loss/lowmiRNAexpressionandmoderate/highexpression.Asmany
as 190 genes were retrieved as differentially expressed between these
Figure 1. The expression of miR-34a. Benign breast epithelium (A). Category 1 (B) represents mild cytoplasmic miR-34a staining, category 2 (C)
moderate staining and category 3 (D) strong staining.
doi:10.1371/journal.pone.0026122.g001
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Category Total 123P P miR-34a
N (%) N (%) N (%) N (%) N (%) 1 vs. 2 and 3
Patient group (n=1172) 0.075 0.164
Sporadic 408 (34.8) 132 (32.4) 182 (44.6) 94 (23.0)
Large families 446 (38.1) 157 (35.2) 176 (39.5) 113 (25.3)
Small families 318 (27.1) 85 (26.7) 143 (45.0) 90 (28.3)
Age (n=1172) 1.771
25 4.690
24
,50 years 406 (34.6) 103 (25.4) 174 (42.8) 129 (31.8)
.50 years 766 (65.4) 271 (35.4) 327 (42.7) 168 (21.9)
Menopause (n=811) 1.073
24 0.002
Premen. 273 (33.7) 63 (23.1) 115 (42.1) 95 (34.8)
Postmen. 538 (66.3) 181 (33.6) 230 (42.8) 127 (23.6)
Histology (n=1041) 4.543
210 1.261
27
Ductal 825 (79.3) 228 (27.6) 364 (44.1) 233 (28.2)
Lobular 216 (20.7) 100 (46.3) 91 (42.1) 25 (11.6)
T (n=1158) 0.137 0.160
1 686 (59.2) 229 (33.4) 289 (42.1) 168 (24.5)
2 399 (34.5) 118 (29.6) 174 (43.6) 107 (26.8)
3 38 (3.3) 10 (26.3) 18 (47.4) 10 (26.3)
4 35 (3.0) 11 (31.4) 13 (37.1) 11 (31.4)
N (n=1154) 0.006 0.012
neg 636 (55.1) 221 (34.7) 268 (42.1) 147 (23.1)
pos 518 (44.9) 144 (27.8) 227 (43.8) 147 (28.4)
M (n=1163) 0.546 0.759
neg 1128 (97.0) 359 (31.8) 481 (42.6) 288 (25.5)
pos 35 (3.0) 12 (34.3) 16 (45.7) 7 (20.0)
Grade (n=1156) 9.042
221 1.548
215
1 281 (24.3) 127 (45.2) 114 (40.6) 40 (14.2)
2 535 (46.3) 188 (35.1) 227 (42.4) 120 (22.4)
3 340 (29.4) 55 (16.2) 149 (43.8) 136 (40.0)
ER (n=1115) 1.730
24 0.003
pos 891 (79.9) 295 (33.1) 389 (43.7) 207 (23.2)
neg 224 (20.1) 51 (22.8) 97 (43.3) 76 (33.9)
PR (n=1113) 0.059 0.063
pos 748 (67.2) 246 (32.9) 321 (42.9) 181 (24.2)
neg 365 (32.8) 100 (27.4) 164 (44.9) 101 (27.7)
HER2 (n=1105) 2.368
24 1.746
25
neg 960 (86.9) 322 (33.5) 402 (41.9) 236 (24.6)
pos 145 (13.1) 23 (15.9) 77 (53.1) 45 (31.0)
Ki-67 (n=1148) 1.391
220 1.132
214
0 282 (24.6) 135 (47.9) 116 (41.1) 31 (11.0)
1 492 (42.8) 152 (30.9) 217 (44.1) 123 (25.0)
2 197 (17.2) 41 (20.8) 87 (44.2) 69 (35.0)
3 177 (15.4) 32 (18.1) 75 (42.4) 70 (39.5)
p53 (n=1097) 1.784
27 1.217
26
neg 875 (79.8) 296 (33.8) 370 (42.3) 209 (23.9)
pos 222 (20.2) 38 (17.1) 103 (46.4) 81 (36.5)
Cyclin E (n=1040) 2.827
210 2.215
26
low 856 (82.3) 291 (34.0) 378 (44.2) 187 (21.8)
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expressed in miR-34a high and low expressing tumours, respectively.
The genes more highly expressed in tumours highly expressing miR-
34a represented the functional families of mitochondria (6 genes), cell
cycle (7 genes), apoptosis (4 genes) and cytoskeleton (4 genes). The
genes more expressed in tumours with low miR-34a expression
covered the functional groups related to immune response (4 genes),
celldeath(6genes),mitochondria(6genes)andcelladhesion(4genes)
among the other functional groups (Table S2). The 190 differentially
expressed genes were systematically screened in search of predicted
targets of miR-34a. To this end, we used integrated prediction by
nine different algorithms that screen for miRNA binding sites in the
39-UTR of the genes. This analysis identified 43 genes with putative
binding sites for miR-34a (Table S3).
Further analysis was carried out on the promoter regions of the
differentially expressed genes (Table S3). A consensus binding site
for p53 was observed in 315 alternative promoters (p=0.812) of
119 differentially expressed genes. Additionally, 110 differentially
expressed genes were predicted to be under the transcriptional
control of MAZ transcription factor (p=0.053). We then looked at
the genes that could form feed forward loops with miR-34a and
p53, MAZ, or both. Four genes were predicted targets of miR-34a
and p53; seven genes were potentially regulated by miR-34a and
MAZ; twenty-nine genes were targets of miR-34a and potentially
Table 2. Multivariate analysis of miR-34a expression with conventional prognostic factors.
10-year breast cancer-specific survival 5-year breast cancer-specific death or
distant metastasis-free survival
Category p-value HR 95% CI Category p-value HR 95% CI
M 4.279
215 7.36 4.47–12.13 T 3.741
210
T 7.194
28 2 vs. 1 7.225
26 2.30 1.60–3.32
2 vs. 1 2.691
24 2.01 1.38–2.92 3 vs. 1 5.026
29 5.74 3.19–10.30
3 vs. 1 5.471
26 4.31 2.30–8.10 4 vs. 1 1.662
26 4.36 2.39–7.96
4 vs. 1 4.961
27 4.98 2.66–9.32 N 2.446
210 3.25 2.26–4.69
Grade 0.003 ER 0.563 1.15 0.72–1.82
2 vs. 1 0.618 1.17 0.63–2.16 PR 0.111 1.39 0.93–2.08
3 vs. 1 0.018 2.19 1.15–4.20 Grade 0.002
N 0.000 3.09 2.11–4.54 2 vs. 1 0.013 2.30 1.19–4.42
ER 0.274 1.32 0.80–2.18 3 vs. 1 0.001 3.47 1.71–7.04
PR 0.022 1.64 1.07–2.51 Ki67 0.724
Ki67 0.425 1 vs. 0 0.717 1.10 0.66–1.81
1 vs. 0 0.216 1.38 0.83–2.28 2 vs. 0 0.355 1.30 0.75–2.27
2 vs. 0 0.275 1.38 0.78–2.44 3 vs. 0 0.877 1.05 0.58–1.90
3 vs. 0 0.865 1.05 0.57–1.95 HER2 0.155 1.31 0.90–1.91
HER2 0.164 1.31 0.89–1.93 P53 0.476 1.14 0.79–1.66
P53 0.582 1.11 0.76–1.64 miR-34a 0.073
miR-34a 0.573 2 vs. 1 0.065 0.70 0.48–1.02
2 vs. 1 0.773 0.94 0.64–1.40 3 vs. 1 0.031 0.63 0.41–0.96
3 vs. 1 0.323 0.80 0.50–1.25
The table shows the results for the Cox’s regression analysis of miR-34a expression with conventional prognostic factors for 10-year breast cancer-specific survival (left)
and 5-year breast cancer-specific death or distant metastasis-free survival (right).
doi:10.1371/journal.pone.0026122.t002
Category Total 123P P miR-34a
N (%) N (%) N (%) N (%) N (%) 1 vs. 2 and 3
high 184 (17.7) 30 (16.3) 76 (41.3) 78 (42.4)
cH2AX
(,2% vs. $2%)
(n=935) 9.508
26 0.001
low 484 (51.8) 170 (35.1) 215 (44.4) 99 (20.5)
high 451 (48.2) 114 (25.3) 191 (42.4) 146 (32.4)
miR-34a, microRNA-34a; T, tumour size; N, nodal status; M, primary metastasis; ER, oestrogen receptor; PR, progesterone receptor; cH2AX, phosphorylated histone
H2AX.
doi:10.1371/journal.pone.0026122.t001
Table 1. Cont.
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the cell cycle (5 genes), alternative splicing (17 genes) and apoptosis
(4 genes) were potentially regulated by miR-34a as well as MAZ
and p53 (Figure 2).
Next, we assayed the clinical importance of the miR-34a
differentially expressed genes by investigating their combinatorial
effect on clinical outcome. For this purpose, we analysed the set of
gene expression profiled 183 breast tumours (GEO ID GSE24450).
In this dataset, the miR-34a gene signature had a significant effect
on the 5-year metastasis-free or breast cancer death-free survival
(p,0.0001) as well as on the 10-year breast cancer-specific survival
(p=0.0003). These results were also confirmed in a public dataset of
unselected breast tumours (n=249) collected at Uppsala County,
Sweden, during the years 1987–1989 (GEO ID GSE4922) [35]
where miR-34a gene signature showed an effect on the 5-year
metastasis-free or breast cancer death-free survival (p=0.038). In
this Swedish dataset, the effect on the 10-year breast cancer-specific
survival was not significant (p=0.155) although a similar trend was
seen (Figure 3).
Discussion
To our knowledge, this is the first study investigating miR-34a
expression in a large clinical series of breast tumour samples and
evaluating the association of miR-34a expression with the tumour
phenotype and outcome in breast cancer patients. In our dataset,
low expression of miR-34a was found in about 32% and high
expression in about 25% of the tumours, with the remaining
tumours showing intermediate expression levels. High miR-34a
expression correlated with an aggressive phenotype of hormone
receptor negative tumours, p53-immunopositive, high tumour
grade andhigh proliferationrateofthe tumours.Despite association
with the aggressive tumour phenotype, however, the miR-34a
expression on its own was not significantly associated witheither 10-
year breast cancer-specific survival or 5-year metastasis-free survival
in univariate analysis. Any survival effect was masked by the strong
correlation of high miR-34a expression with the known prognostic
factors, indicating miR-34a expression activation per se as a marker
for an aggressive breast tumour. However, multivariate analysis,
adjusting for the conventional adverse prognostic factors to evaluate
the independent effect of miR-34a expression on breast cancer
survival, indicated that miR-34a expression in fact was associated
with a lower risk of recurrence or death from breast cancer. This
findingwas significant especially in the analysisof 5-year survival for
distant metastasis or breast cancer specific death combined, with a
similar though not statistically significant tendency on the 10-year
breast cancer-specific survival. This may be due to lower statistical
power in the 10-year analysis with breast cancer death as the only
endpoint. In addition, the 10-yearanalysis could also reflect possible
effects of treatment of metastatic breast cancer which might modify
the patient survival in miR-34a subgroups. Overall, these results are
consistent with the proposed tumour suppressor role of miR-34a
and previous results on epithelial ovarian cancer showing that
reduced expression of miR-34 family members is associated with
metastatic clinical stage [17]. These results also suggest that miR-
34a may be considered as a suppressor of metastasis, but this needs
to be further evaluated in future functional studies.
The transcription factor p53 is known to bind upstream of the
transcription start site of miR-34a regulating its expression [10].
Moreover, expression of miR-34a has been previously found to be
reduced in 25% of breast cancer cell lines due to the methylation
of its promoter [22] as well as in cell lines derived from basal-like
tumours, which has been suggested to be due to the frequent p53
mutations in these tumours [21]. In our present study, 17% of
tumours with positive staining for 53, suggesting p53 protein
accumulation due to a mutated p53 gene, showed low miR-34a.
However, as a whole, high levels of p53 protein correlated strongly
with high miR-34a expression and vice versa, low miR-34a
expression correlated with p53 negative tumours. Potential
molecular basis for these findings is discussed below.
Our present study furthermore revealed that high miR-34a
expression correlates with high cH2AX expression levels. The
Figure 2. Mir-34a Feed Forward Loops (FFL). Groups of genes that are predicted to be targets of miR-34a and under the control of MAZ, p53, or
both. The text color indicates the upregulated (red) and the downregulated genes (blue).
doi:10.1371/journal.pone.0026122.g002
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upstream DNA damage signalling kinases ATM and ATR, and it is
generally regarded as an indicator of activated response to DNA
damage including replication stress, a condition shared by a wide
spectrum of malignancies including breast cancer [37–39]. High
cH2AX, as well as p53 have been implicated in DNA damage
response, cellular stressand apoptosis [39,40] and the high miR-34a
expression in these tumours may reflect the response to the ongoing
DNA damage and cellular stress. Interestingly, several genes among
the 190 genes we found as differentially expressed in tumours
subdivided by miR-34a expression are associated with functional
families such as apoptosis or they encode proteins resident in the
mitochondria. In addition, we identified 119 of the differentially
expressed genes in tumours with different miR-34a levels to be
potential targets of p53. p53 binding was not significantly enriched
in the promoters of the differentially expressed genes (Table S3,
enrichment p=0.8), however, this is not surprising as most of the
human transcription factors are expressed in most of the cells in the
human body where they act as general transcription facilitators (e.g.
p53) while only a small portion of them is expressed in certain
conditions and devoted to more specific functions [41]. Instead, the
activationofcertaincombinationsoftranscriptionfactorsleadtothe
Figure 3. Gene signature survival analysis. Kaplan-Meier plots for 10-year breast cancer-specific survival (A) and 5-year metastasis-free or breast
cancer death survival (C) in the Helsinki data set (GSE24550); 10-year breast cancer-specific survival (B) and 5-year metastasis-free or breast cancer
death survival (D) in the Uppsala data set (GSE4922). For each study, the patients were split into two groups according to the expression levels of the
signature genes. Subsequently, the survival rates of the two groups were compared by log-rank test.
doi:10.1371/journal.pone.0026122.g003
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human body [42].
Previous studies have suggested that miR-34a is a target of p53
and itself acts as a tumour suppressor inducing cell cycle arrest in
G1-phase [9,10], senescence and apoptosis [11–13]. The unex-
pected correlation between high p53 protein level and enhanced
miR-34a expression observed in our clinical specimens might
reflect several molecular scenarios. In some tumours, positive p53
staining may reflect activation and stabilisation of a functional p53
protein in response to DNA damage and cellular stress [37,40] and
consequently p53-mediated up-regulation of miR-34a. In addition,
the miR-34a itself might be under transcriptional control of also
other genes than p53, and such alternative regulation may operate
in the tumours where high p53 expression represents mutated
dysfunctional p53. Indeed, the genome-wide mRNA profiling by
miR-34a expression in our samples has highlighted a number of
other differentially expressed genes whose expression might be
under the control of other transcription factors (Table S3).
Particularly, 110 differentially expressed genes were predicted to
be under the transcriptional regulation of MAZ transcription
factor (Table S3, enrichment p=0.05), which is also computa-
tionally predicted to target miR-34a. Interestingly, these genes
represented functional groups such as mitochondria (12 genes),
cell death (10 genes) and cell cycle (7 genes) (Figure 2). MAZ gene
locus maps on 16p11.2 and it has been found up-regulated in
breast cancer [43]. MAZ is known to modulate PPARgamma1 (the
peroxisome proliferator-activated receptor gamma 1) and down-
regulation of PPARgamma1 directly, or via down-regulation of
MAZ, was shown to inhibit cell growth and to induce apoptosis in
MCF-7 breast cancer cells [44]. Therefore, expression of MAZ and
its targets including miR-34a may play a pro-survival role in the
context of breast cancer, and possibly of other tumours.
Under the assumption that co-expressed genes may also be co-
regulated, overall our results suggest that the transcription of miR-
34a in our breast tumour series can indeed be under the control of
additional transcription factors and due to alternative regulatory
circuits, and hence, further characterisation of the miR-34a
regulatory region will be needed in follow-up studies. Further,
taking advantage of recent data on regulatory loops involving
transcription factors and miRs [45], we highlighted groups of
genes forming functional feed forward loops together with miR-
34a, MAZ and p53 (Figure 2). For example, high levels of miR-
34a are associated with inhibition of its target AKT interacting
protein (AKTIP), which is also a putative target of MAZ and p53.
The AKTIP oncogene maps to chromosome 16q12.2, its product
operates as part of the PI3K-AKT-pathway, and several findings
link miR-34a also to this pathway [46].
On the other hand, we retrieved the metalloproteinase 17
(MMP17) to be up-regulated in the tumours with high expression of
miR-34a. MMP17 was also predicted to be a target of miR-34a and
potentially under of the transcriptional control of MAZ and p53.
High expression levels of MMP17 have been associated with
invasiveness of breast cancer, where inhibition of its expression by
small interferring RNAs resulted in a non-invasive phenotype
[47]. Furthermore, in tumours highly expressing miR-34a, its
target TP53INP1 (p53-induced nuclear protein 1) was inhibited.
TP53INP1 is a stress-induced protein involved in cell cycle arrest
and apoptosis. Low levels of TP53INP1 have been observed in
breast carcinoma as compared to normal breast tissue [48]. Thus,
examples such as TP53INP1 would fit a potential context-
dependent tumour-promoting role of miR-34a in a subset of breast
tumours in vivo. In line with the emerging view of micro-RNA
regulatory mechanisms, these findings suggest complex parallel
or even opposing regulatory relationships both upstream and
downstream of miR-34a in breast tumours that are not easily
dissected in cell line models.
We further investigated the effect on the breast cancer survival and
relapse of the expression pattern of the 190 genes affected by the miR-
34a levels in our gene expression dataset consisting of 183 breast
tumours. Additionally, an independent dataset of tumours collected at
Uppsala County was also similarly tested. The aim of this analysis was
to test whether the overall signature genes are able to identify groups
of patients with different survival rates. Here we followed the strategies
successfully utilized by Lukes et al. [49]: the patients are divided into
two groupsby clusteringanalysis based on the overall expression ofthe
signature genes. Finally, the differential survival effect in the two
patient groups is evaluated. Altogether, our results indicated that the
expression signature of 190 genes is associated with the breast cancer
death and relapse, especially when the effect was investigated at
5 years from the diagnosis. This suggests that the network of genes
co-regulated with and targeted by miR-34a form a functional group of
down-stream effectors with a prognostic effect.
In conclusion, we have shown that while miR-34a expression
activation is a marker for aggressive breast cancer tumour phenotype
per se, it excerts an independent effect for a lower risk of recurrence or
death from breast cancer supporting it’s proposed role as a tumour
suppressor also in breast cancer. The gene expression analysis further
revealed an effect of the miR-34a signature on the clinical outcome,
which was also observed in an independent dataset. Our results
suggest that MAZ and p53 transcription factors co-operate in
m o d u l a t i n gm i R - 3 4 a ,a sw e l la st h eexpression of several miR-34a
target genes in several pathways, including PI3K-AKT, with an
impact on relapse and survival of breast cancer patients. Overall, these
results identify a network of genes co-regulated with and targeted by
miR34a, and thereby reveal a novel aspect of breast cancer biology,
with implications for prediction of clinical outcome.
Supporting Information
File S1 Supplementary material & methods. A document
describing the patients series and breast tumour samples, and
detailed description of the methods used.
(DOC)
Table S1 Differentially expressed genes. The table con-
tains the 190 genes (in rows) differentially expressed inlow versus high
miR-34a expressing tumours. The genes are ordered according to
the decreasing log2 fold change. The gene names (GeneName
column), the gene symbol (GeneSymbol column) and the Entrez
Gene IDs (EntrezGeneID column) are provided. Additionally, the
log2 fold change (logFC column), the average expression throughout
the dataset (AveExpr column), the t-test values (t column) and the
p-values (P.Value columns) are also reported.
(XLS)
Table S2 Functional analysis of the differentially ex-
pressed genes. The file reports the DAVID annotation tool
results and it consists of 4 sheets containing the functional clustering
(FClust) and the functional charts (FChart) of the upregulated genes
(UP) and the downregulated genes (DN). The functional clustering
tables contain the functional families (in rows) organized in groups
according to the shared genes. For each cluster, the enrichment
scoreis provided. Inaddition,thecategory, the familyname (Term),
the number of genes retrieved in the family (Count), the enrichment
percentage (%) the enrichment p-value (PValue) are provided and
the gene symbols (Genes) are also reported. In the functional chart
tables, the functional families are ordered according to the
increasing p-values.
(XLS)
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34a targets. The file consists of 5 sheets. The MatInspector table
lists the transcription factor matrices (Matrix Family), the
enrichment p-value for potential binding on the promoters of the
differentially expressed genes (P-value), the overall number of
matches (No. of matches) and the number of promoters with
predicted consensus (No. of sequences). The other tables report the
differentially expressed genes that are targeted by miR-34a
(mir34a table), the miR-34a targets under the control of p53
(mir34a+p53), MAZ (mir34a+MAZ) or both (mir34a+MAZ+p53).
The columns of these tables are as in table S1.
(XLS)
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